Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its...
Vascepa to be available on or about February 18, 2020, supported by a national Cardiovascular salesforce Vascepa becomes the first and only Health Canada-approved medication for reducing...
If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia TORONTO, Jan. 23, 2020 /CNW/ - HLS Therapeutics...
Peak-year sales estimate increases to CAD$200-300 million, from CAD$150-250 million Commercial launch expected to take place in the mid-February 2020 timeframe Vascepa is the subject of numerous...
Health Canada approval follows priority review for Vascepa Vascepa becomes the first and only HC-approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in the...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that the Endocrinologic and...
Revenue of $13.4 million, Adjusted EBITDA of $8.0 million and Cash from Operations of $6.8 million Paid a quarterly dividend of C$0.05 per outstanding common share Subsequent to quarter-end,...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its...
From a single drop of blood from the tip of a finger, Athelas One WBC System generates white blood cell counts and neutrophils percentages in minutes The device could help lower the most commonly...
À partir d'une seule goutte de sang du bout d'un doigt, le système d'analyses Athelas One fournit la numération des globules blancs et le pourcentage de neutrophiles en quelques minutes. Le...
Revenue of $13.6 million, Adjusted EBITDA of $8.1 million and Cash from Operations of $9.0 million Filed the New Drug Submission for Vascepa® with Health Canada after having been granted Priority...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held on June 21, 2019 in Toronto, Ontario. A total of 23,983,572 Common...
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO, June 5, 2019...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will present at the...
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ ETOBICOKE, ON, May 14,...
Revenue of $13.2 million, Adjusted EBITDA of $8.3 million and Cash from Operations of $8.3 million Granted priority review status for Vascepa™ by Health Canada, which could reduce the review...
Cardiovascular disease is the leading cause of death globally1 NDS for Vascepa is supported by data from the REDUCE-IT™ trial, an international, multi-center cardiovascular outcomes study that...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Greg Gubitz, CEO, will...
Cardiovascular disease is the leading cause of death globally1 HLS New Drug Submission (NDS) for Vascepa is supported by data from the REDUCE-IT™ trial, an international, multi-center...
Revenue of $61.4 million, Adjusted EBITDA of $41.1 million and Cash from Operations of $32.7 million for the year-ended December 31, 2018 REDUCE-IT™ cardiovascular outcomes study of Vascepa®,...
Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa Usage Grow Over Time TORONTO, March 19, 2019 /CNW/ - HLS Therapeutics...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that on March 16, 2019, Amarin...
From a single drop of blood from the tip of a finger, the point-of-care technology generates white blood cell counts and neutrophils numbers in minutes When approved in Canada, the Athelas One...